Vitrafy Life Sciences's Cryopreservation Ecosystem Used In USAISR's Phase Two Platelet Cryopreservation Study, Shares Rise 5%

MT Newswires Live
Apr 08

Vitrafy Life Sciences (ASX:VFY) said the US Army Institute of Surgical Research (USAISR) completed the phase two testing of its platelet cryopreservation study using Vitrafy's cryopreservation ecosystem, according to a Wednesday Australian bourse filing.

The study sought to confirm the consistency of earlier results and further characterise performance across multiple cryopreservation formulations. The work was carried out under the ongoing cooperative research and development agreement (CRADA) between the firm and the US Army.

Its shares rose 5% in recent trading on Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10